Stockpolly
Search
Delisting risk
IMNN · NASDAQ · Biotechnology

Imunon (IMNN)

Developing localized DNA immunotherapy for advanced ovarian cancer.

$1.70
Pre-market+0.13 (+7.94%)
At close$1.58(−1.56%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000030200000
Gross profit0000−30−200000
465524233443
Research & development243332212221
22222222221,9691
General & administrative22222022221,9691
Other expenses0000−30−2000−1,9670
Operating income−4−6−5−5−5−4−4−3−3−4−4−3
010000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income000000000000
Income before tax−3−5−5−5−5−4−4−3−3−4−4−3
Net income from continuing operations−3−5−5−5−5−4−4−3−3−4−4−3
Net income−3−5−5−5−5−4−4−3−3−4−4−3
EPS, basic−$4.84−$6.78−$6.84−$6.64−$4.38−$3.65−$3.68−$1.87−$1.16−$1.99−$0.84−$0.54
EPS, diluted−$4.84−$6.78−$6.84−$6.64−$4.38−$3.65−$3.68−$1.87−$1.16−$1.99−$0.84−$0.54
Weighted average shares, basic111111113255
Weighted average shares, diluted111111113255
EBITDA−3−6−5−5−5−4−4−3−3−4−4−3
Depreciation & amortization000000000000
EBIT−3−6−5−5−5−4−4−3−3−4−4−3